Amgen
Executive Summary
Company will acquire Medford, Mass.-based Kinetix for $170 mil. in stock. Privately held Kinetix specializes in discovering small molecule drugs in the field of protein kinase inhibition, and has oncological and anti-inflammatory agents in preclinical development. Kinetix CEO Nick Lydon, PhD, will relocate to Thousand Oaks, Ca., to become Amgen's VP-small molecule drug discovery, while Kinetix VP-R&D and Chief Scientific Officer David Armistead, PhD, will become VP-chemistry and will head Amgen's research programs in the Boston area. While remaining in their facilities at present, Kinetix' 40 employees may eventually move to Amgen's new research & drug discovery facility being built in Cambridge, Amgen said